BioTime and its subsidiary companies are committed to delivering novel products based on regenerative medicine to patients with serious diseases and degenerative conditions for which there are no cures.
Asterias Biotherapeutics is advancing its pluripotent stem cell-based therapies in the world’s first human embryonic stem cell-based human clinical trial. AST-OPC1 is in a Phase I trial for spinal cord injury rehabilitation and AST-VAC2 is advancing toward clinical development for non-small cell lung cancer.
ES Cell International Pte Ltd
ES Cell International Ltd. Pte., is BioTime’s Singapore-based subsidiary that provides the world’s first clinical grade human embryonic stem cells through BioTime’s ESI BIO division.
ESI BIO is a division of BioTime that manufactures and markets stem cell-related research products developed by BioTime and BioTime’s family of companies. These include clinical grade and research grade ESI human embryonic stem cell lines and the HyStem® hyaluronan-based hydrogels. ESI BIO also markets BioTime’s unique PureStem® embryonic progenitor cells and a host of reagent products for cell culture and differentiation.
OncoCyte Corporation is focused on developing proprietary diagnostic products to meet unmet needs in the detection and screening of lung, breast and bladder cancer.
With the world’s largest selection of pure musculo-skeletal progenitor stem cells lines provided through BioTime's PureStem embryonic progenitors, OrthoCyte Corporation is developing cellular therapies designed to reverse damage in the spine from age-related injuries.
ReCyte is focused on regenerative medicine for cardiovascular and metabolic diseases. We are developing cell-based and secreted product therapeutics using highly pure and scalable PureStem® progenitor stem cell lines. These lines have significant advantages including safety, reliability, and ease of manufacturing.